{"filings":[{"id":96000,"accession_number":"0001193125-26-204125","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics signs manufacturing deal with Emergent for SAB-142; $36M minimum spend post-FDA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Master Manufacturing Services Agreement executed April 28, 2026, with Emergent BioSolutions Canada Inc. for SAB-142.","Term runs 5 years from FDA approval; minimum aggregate spend of $36 million after approval.","Emergent has exclusive manufacturing rights during term; SAB may seek alternative source in limited cases.","Commercial batch price to be set in amendment within 18 months of anticipated commercial sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95999,"accession_number":"0001193125-26-168569","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB BIO reports positive Phase 1 SAB-142 data: C-peptide preservation, T cell exhaustion, improved glycemic control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 4 T1D participants on SAB-142 2.5 mg/kg preserved C-peptide; 3 of 4 achieved super responder status with C-peptide above baseline at Day 120.","SAB-142 induced CD4+ Tconv cell exhaustion (TIGIT+ levels) correlating with C-peptide preservation, consistent with rabbit ATG mechanism.","Mean CGM time in range improved from 73% at baseline to 85% at Day 120, with no increase in exogenous insulin use.","Phase 2b SAFEGUARD trial topline data expected in 2H 2027; CEO cites potential best-in-class profile for T1D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109493,"accession_number":"0001193125-26-114730","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics prices $85M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 19.3M shares at $3.85/share and pre-funded warrants for 2.75M shares at $3.8499 each.","Gross proceeds expected ~$85M; net proceeds ~$69.7M ($81.7M if over-allotment option exercised).","Proceeds to fund clinical development of SAB-142 (anti-thymocyte immunoglobulin) for type 1 diabetes.","Offering led by Jefferies, UBS, Citigroup, Barclays; expected to close March 19, 2026.","30-day over-allotment option for additional 3.31M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109492,"accession_number":"0001193125-26-099376","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"SAB-142 Phase 1 data shows C-peptide preservation in established T1D patients at Day 120","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["T1D cohort (n=6): 4 treated with SAB-142 (2.5 mg/kg) showed no decline in C-peptide at Day 120; mean values increased above baseline.","Placebo participant (n=1) showed C-peptide decline consistent with predicted disease progression.","Biomarker evidence of T cell exhaustion supports mechanism of action, per KOL Michael Haller, MD.","SAFEGUARD Phase 2b trial enrolling new-onset Stage 3 T1D patients; topline data expected 2H 2027.","Phase 1 previously met safety/PD objectives, enabling advancement to registrational trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109491,"accession_number":"0001193125-26-010515","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics posts updated corporate presentation; no financial or operational details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 Regulation FD; presentation posted on company website.","No specific financial metrics, pipeline updates, or guidance changes provided in the filing.","Presentation titled 'Modifying Disease, Delaying Progression, Transforming Treatment' suggests therapeutic focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109490,"accession_number":"0001193125-26-005487","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Bio appoints David Zaccardelli as Chair and Rita Jain as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Zaccardelli, Pharm.D., appointed Chair of the Board effective January 5, 2026; led Ohtuvayre launch at Verona Pharma.","Rita Jain, M.D., appointed independent director; brings autoimmune/inflammatory disease drug development expertise.","Appointments follow RA Capital's nomination rights from July 2025 private placement; CEO Samuel Reich remains on board.","Company advancing SAB-142, a fully human anti-thymocyte immunoglobulin for type 1 diabetes and autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126007,"accession_number":"0001193125-25-335267","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SAB Biotherapeutics establishes new $75M ATM equity program via UBS, terminates prior $20M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered sales agreement with UBS Securities for at-the-market offering of common stock up to $75 million aggregate offering price.","Prior $20M ATM program with Cantor Fitzgerald terminated effective Dec 17, 2025; Cantor waived 60-day restriction.","Net proceeds intended for pipeline development, general corporate and working capital purposes.","Agent fee up to 3% of gross proceeds; program may be terminated by either party on 10 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142741,"accession_number":"0001193125-25-225119","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Christine Hamilton and Jeffrey Spragens resign from SAB Biotherapeutics board; size cut to nine","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christine Hamilton and Jeffrey Spragens resigned as board members effective September 30, 2025.","Board size reduced from 11 to 9 directors, per July 2025 letter agreement with RA Capital Healthcare Fund.","Resignations were not the result of any disagreement with management or company policies.","The changes follow terms of the company's July 2025 private placement of securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142740,"accession_number":"0001193125-25-220721","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"SAB Biotherapeutics shareholders approve 24.18M share increase and Series B conversion at less than minimum price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing plan shares by 24,180,000 to 31,932,466 total; evergreen cap raised to 73,750,000 shares.","Approved issuance of over 19.99% of outstanding common stock upon Series B Preferred conversion at less than Nasdaq minimum price, deemed a potential change of control.","Proposal 1 (conversion) passed with 5,502,026 votes for, 515,275 against, 35,744 abstentions.","Proposal 2 (plan amendment) passed with 5,089,862 votes for, 951,598 against, 11,585 abstentions.","Approximately 54.5% of outstanding shares were present, forming a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142739,"accession_number":"0000950170-25-097078","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["1.01","3.02","8.01","5.03","9.01"],"status":"ready","headline":"SAB Bio raises $175M in oversubscribed private placement; Sanofi participates; cash runway into mid-2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $175M from sale of Series B convertible preferred stock and warrants; conversion price $1.75 per common share.","Investors include strategic partner Sanofi, RA Capital, Commodore Capital, Vivo Capital, Blackstone Multi-Asset, and others.","Proceeds to fully fund Phase 2b SAFEGUARD study of SAB-142 in Stage 3 T1D and extend cash runway into middle of 2028.","Warrants exercisable for up to 1.5M additional preferred shares, potentially yielding additional $284M in gross proceeds.","Company received FDA alignment on Phase 2b SAFEGUARD trial design during a Type B meeting on May 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142738,"accession_number":"0000950170-25-096645","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SAB Biotherapeutics elects four Class I directors, ratifies auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Dr. William Polvino, Scott Giberson, Erick Lucera, and Dr. Jay S. Skyler as Class I directors for three-year terms.","Appointment of EisnerAmper LLP as independent auditor for fiscal year 2025 ratified with 6,374,363 votes for, 238,327 against.","Quorum of 71.38% achieved; 6,633,125 shares present out of 9,291,697 outstanding.","Broker non-votes of 2,154,677 on director elections; each director received over 4.3 million votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179017,"accession_number":"0000950170-25-014627","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"SAB Biotherapeutics enters 5-year lease for Sioux Falls lab/office space from Sanford Health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leases 21,014 sq ft at 2301 E 60th St N, Sioux Falls, SD; term effective Feb 1, 2025 through Dec 31, 2029.","Annual rent $601,630.82 ($28.63/sq ft), paid monthly at $50,135.90; January 2025 rent paid under prior lease.","Annual rent escalates by greater of 2% or CPI starting Jan 1, 2026; either party may terminate with 90 days' notice.","Tenant responsible for maintenance and repairs; Landlord pays utilities, taxes, and base-building maintenance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179016,"accession_number":"0000950170-25-009474","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics reports positive Phase 1 topline results for T1D therapy SAB-142; plans Phase 2b in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of SAB-142 met primary safety and PD objectives; generally well-tolerated, no serum sickness or anti-drug antibodies at target dose.","SAB-142 showed sustained immunomodulation with MoA analogous to rabbit ATG, correlative to C-peptide preservation.","Company plans to advance SAB-142 into Phase 2b trial in 2025 for adult and pediatric patients with new-onset T1D.","Results presented at R&D webinar on Jan 28, 2025; KOL Michael Haller, MD from Univ of Florida participated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211971,"accession_number":"0000950170-24-104564","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SAB Bio completes Phase 1 healthy-volunteer enrollment; SAB-142 shows no serum sickness at 2.5 mg/kg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of SAB-142 for type 1 diabetes completed all planned healthy-volunteer cohorts; no serum sickness observed at target 2.5 mg/kg dose.","Company now enrolling type 1 diabetes patients in the last cohort of the Phase 1 study.","Topline Phase 1 data readout expected by end of 2024.","SAB-142 is a first-in-class human anti-thymocyte immunoglobulin with differentiated safety profile compared to rabbit ATG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211970,"accession_number":"0000950170-24-088247","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics appoints Lucy To as CFO effective August 12, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucy To appointed CFO; Mark Conley reassumes VP Finance role effective August 12.","To brings 18+ years experience; most recently MD at Wells Fargo Healthcare IB.","Employment agreement: $475K base, $125K signing bonus, 125K stock options vesting over 4 years.","Top-line Phase 1 data for T1D drug SAB-142 expected by end of 2024 per press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230788,"accession_number":"0000950170-24-078622","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SAB Biotherapeutics shareholders elect directors, approve equity plan amendment, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Samuel J. Reich, Christine Hamilton, and Eddie J. Sullivan as Class III directors for three-year terms.","Approved amendment to 2021 Omnibus Equity Incentive Plan, increasing share reserve by 3.9M to 5.5M shares.","Ratified EisnerAmper LLP as independent registered public accounting firm for FY 2024.","Voting results: For director elections, votes ranged from 4.89M to 5.15M with ~1.3M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230787,"accession_number":"0000950170-24-066856","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics CFO Michael King resigns effective June 4; Mark Conley appointed Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michael King resigns effective June 4, 2024 to become CEO at private oncology company; will remain advisor through year-end.","Mark Conley, current VP Finance, appointed Interim CFO; board launches formal search for permanent replacement.","Conley's compensation unchanged under existing agreement: $303K base salary, bonus eligibility, and 250,000 stock options.","Company confirms FY2024 outlook and upcoming Phase 1 topline data readout for lead candidate SAB-142."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230786,"accession_number":"0000950170-24-062656","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for SAB Biotherapeutics' T1D therapy SAB-142 Phase 1 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes.","Phase 1 HUMAN trial is randomized, double-blind, placebo-controlled, single-ascending dose (0.03-2.5 mg/kg).","Enrollment of US patients with type 1 diabetes now permitted; third cohort dosed with no serum sickness.","Topline results from the MELD-ATG study expected in 2025.","SAB-142 aims to delay onset or progression of stage 3 type 1 diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230785,"accession_number":"0000950170-24-054868","cik":1833214,"company_name":"SAB Biotherapeutics, Inc.","ticker":"SABS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SAB Biotherapeutics Appoints Dr. Jay Skyler to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay Skyler appointed as Class I director, effective May 3, 2024, to serve until 2025 annual meeting.","Skyler is Professor of Medicine at University of Miami, former President of American Diabetes Association, and served on boards of DexCom, Amylin, and MiniMed.","His appointment brings deep Type 1 diabetes expertise to SAB's board, supporting SAB-142 immunotherapy program.","No material transaction or family relationship with any director or officer; compensation consistent with non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":275270742.0472441,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}